The latest from Velocity Clinical Research

Case Study: Doubling the Average Participation Rate of Diverse Populations in Cognivue’s FOCUS Study

March 22, 2023

Neuroscience company Cognivue enrolled more than double the national average participation rate of diverse populations in its Further the Objective and Clinical Understanding of Cognivue Study (FOCUS) study. Velocity supported the study by enrolling the entirety of the study’s more than 1,500 subjects across … Read more

8 Insights From 9,000+ Real Clinical Trial Participant Surveys

January 29, 2023

Clinical trials — especially high-volume trials — are primarily designed to collect quantitative data. Collecting and reviewing qualitative data and experiential feedback from trial participants is rarely prioritized. Before being acquired by Velocity Clinical Research, Meridian Clinical Research built an in-house surveying system to … Read more

Velocity Announces Three Leadership Hires in Europe

January 24, 2023

Velocity Clinical Research (“Velocity”), the largest integrated research site organisation globally, today announces it has strengthened its European senior executive team with three strategic hires, as the firm continues its expansion in the region. Évelyne Newton joins as Vice President of Business Development, Sandra … Read more

Clinical Trials: What You Need to Know for 2023

January 23, 2023
Clinical Trials What You Need to Know for 2023

1: Consolidation and scale of the market It is well known that fragmentation of the clinical sites business has been identified as a market opportunity by private equity firms. As a result of a PE capital injection, there has been increased merger and acquisition … Read more

Brandon Essink, MD, CPI, is Lead Author of Article Providing Update on Zika Virus Vaccine Development

January 20, 2023

Brandon Essink, MD, CPI, was the lead author of the article, “The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials”. Dr. Essink oversaw … Read more

Velocity Clinical Research begins European expansion with German site acquisition

January 9, 2023

DURHAM, N.C., July 27, 2022 /PRNewswire/ — Velocity Clinical Research (“Velocity”), the leading integrated research site organisation, today announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount. The acquisition is the first in a series of deals lined up across … Read more

Velocity Clinical Research Acquires Meridian Clinical Research, Creates Largest Global Research Sites Business

December 15, 2022

Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces its acquisition of Meridian Clinical Research for an undisclosed amount. The deal makes Velocity the largest dedicated research site organization in the world with approximately 80 sites in the U.S. and Europe, … Read more

Velocity Publishes 2022 U.S. Patient Survey

September 27, 2022

In 2022 Velocity undertook its first national survey in the U.S. of patients who have previously taken part in clinical research, receiving 1,129 responses. We wanted to gauge views and attitudes on taking part in clinical research, including thoughts regarding decentralization and the use … Read more

Velocity Clinical Research growth skyrockets with eight site acquisitions

September 1, 2022

Velocity Clinical Research (“Velocity”), the leading integrated research site organization, today announces it has acquired MedPharmics, a multi-site company based in the US. The acquisition brings Velocity’s total number of locations to 40 sites across 19 U.S. states and Europe. With this acquisition, Velocity … Read more

First Participant Enrolled in Moderna’s Phase 1 Epstein-Barr Virus Vaccine (mRNA-1189) Trial

January 5, 2022

Meridian Clinical Research, now part of Velocity Clinical Research, enrolled the first participant in Moderna’s Phase 1 clinical trial for an Epstein-Barr virus (EBV) vaccine candidate (mRNA-1189). Congratulations to Moderna, and to Brandon Essink, MD, CPI, and the team in Omaha, Nebraska! Read the … Read more

Meridian Clinical Research, Now Part of Velocity, Wins Inaugural Excellence in Patient Centricity Award

October 5, 2021

Meridian Clinical Research, now part of Velocity Clinical Research, won the first ever Excellence in Patient Centricity Award from the Society for Clinical Research Sites (SCRS). The award was presented to Meridian at the 2021 Global Site Solutions Summit in Hollywood, FL. Sponsored by … Read more

U.S. Department of Health and Human Services (HHS) Officials Meet With Leaders to Discuss COVID-19 Vaccine Clinical Trials and Patient Recruitment

October 16, 2020

Officials from the U.S. Department of Health and Human Services (HHS) visited with leaders from Meridian Clinical Research (now part of Velocity Clinical Research) in Savannah, GA. Following a tour of the company’s internal medicine site in Savannah, the group held a roundtable to discuss … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Site Representative in Office

Quality. Continuity. Velocity.